Alveolus Bio is pursuing the development of novel FDA-approved therapeutics to address chronic respiratory illnesses.
Alveolus Bio has raised $2.0M in total funding. The most recent round was Seed. The last funding was announced in July 2025.
Alveolus Bio's investors include Shilpa Medicare, Innovate Alabama, National Heart, Lung and Blood Institute.
Alveolus Bio is headquartered in Birmingham, United States.
Alveolus Bio is pursuing the development of novel FDA-approved therapeutics to address chronic respiratory illnesses.
Alveolus Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alveolus Bio — Funding & Investors." VCBacked, July 25, 2025, https://www.vcbacked.co/company/alveolus-bio. Accessed September 30, 2026.
VCBacked. (2025). Alveolus Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/alveolus-bio
{{cite web |title=Alveolus Bio — Funding & Investors |url=https://www.vcbacked.co/company/alveolus-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated